Cancer Research UK and CRIS fund lung cancer vaccine research

25 Mar 2024
www.pharmaceutical-technology.com
VaccineImmunotherapy
Cancer Research UK and CRIS fund lung cancer vaccine research
Preview
Source: Pharmaceutical Technology
The potential vaccine will utilise technology similar to the successful Oxford-AstraZeneca Covid-19 vaccineCovid-19 vaccine. Credit: Mike Mareen / Shutterstock.com.
Cancer Research UK and the CRIS [Cancer Research Innovation in Science] Cancer Foundation have awarded a £1.7m ($2.1m) grant to researchers at the University of Oxford, the Francis Crick Institute and University College London to develop the lung cancer vaccine LungVax.
The funds will support the creation of the world’s first vaccine to prevent lung cancer in high-risk individuals.
The potential vaccine will use technology similar to the successful Oxford-AstraZeneca Covid-19 vaccineCovid-19 vaccine.
Similar to standard vaccines, LungVax will use neoantigens – harmless proteins from the surface of cancer cells – to train the immune system to recognise and fight abnormal lung cells.
Neoantigens result from mutations in the cell’s DNA that signal the immune system to target and destroy the cells, potentially stopping lung cancer before it starts.
See Also:
Birmingham University to develop lollipop for mouth cancer detection
Cancer Research UK and CRIS fund lung cancer vaccine research
Preview
Source: Pharmaceutical Technology
Verastem files patent for combination treatment of FAK inhibitor and immunotherapy for cancer
Cancer Research UK and CRIS fund lung cancer vaccine research
Preview
Source: Pharmaceutical Technology
The research team will conduct laboratory tests to determine if the vaccine can effectively trigger an immune response. On obtaining positive test results, it will be progressed to clinical trials.
Up to 2026, the team will receive a grant supporting lab research and the initial production of 3,000 vaccine doses at the Oxford clinical biomanufacturing facility.
The vaccine could be expanded to larger trials targeting high-risk groups such as current or former smokers aged between 55 and 74 years.
These demographics are eligible for targeted lung health checks in some UK regions.
Researchers estimate that the vaccine could address approximately 90% of all lung cancers.
Cancer Research UKCancer Research UK chief executive Michelle Mitchell stated: “Projects like LungVax are a really important step forward into an exciting future, where cancer is much more preventable.
“We’re in a golden age of research and this is one of many projects which we hope will transform lung cancer survival.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.